BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12607598)

  • 21. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.
    Burkadze G; Khardzeishvili O; Gudadze M; Tsikhiseli G; Turashvili G
    Georgian Med News; 2010; (184-185):51-60. PubMed ID: 20834076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
    Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The expression of bcl-2, P53 and c-erbB-2 onco-proteins in breast cancer and their clinicopathological significance].
    Gao L; Ding H; Deng Y
    Zhonghua Bing Li Xue Za Zhi; 1996 Jun; 25(3):165-8. PubMed ID: 9275673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosome 1 aneusomy with 1p36 under-representation is related to histologic grade, DNA aneuploidy, high c-erb B-2 and loss of bcl-2 expression in ductal breast carcinoma.
    Farabegoli F; Ceccarelli C; Santini D; Trerè D; Baldini N; Taffurelli M; Derenzini M
    Int J Cancer; 1996 Oct; 69(5):381-5. PubMed ID: 8900371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma.
    Yang Q; Sakurai T; Jing X; Utsunomiya H; Shan L; Nakamura Y; Nakamura M; Oura S; Suzuma T; Yoshimura G; Umemura T; Kokawa Y; Kakudo K
    Pathol Int; 1999 Sep; 49(9):775-80. PubMed ID: 10504548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
    Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
    Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleomorphic carcinoma of the breast: clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma.
    Silver SA; Tavassoli FA
    Histopathology; 2000 Jun; 36(6):505-14. PubMed ID: 10849092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
    Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
    Yoshikawa K; Honda K; Inamoto T; Shinohara H; Yamauchi A; Suga K; Okuyama T; Shimada T; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
    Clin Cancer Res; 1999 Jun; 5(6):1249-61. PubMed ID: 10389907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
    Yoshida R; Ohuchi N; Kimura N
    Oncol Rep; 2002; 9(6):1363-7. PubMed ID: 12375049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
    Querzoli P; Albonico G; di Iasio MG; Ferretti S; Rinaldi R; Cariello A; Pedriali M; Matteuzzi M; Maestri I; Nenci I
    Breast Cancer Res Treat; 2001 Mar; 66(2):135-42. PubMed ID: 11437099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
    Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
    Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlations of breast carcinoma biomarkers and p53 tested by FASAY and immunohistochemistry.
    Vagunda V; Smardová J; Vagundová M; Jandáková E; Zaloudík J; Koukalová H
    Pathol Res Pract; 2003; 199(12):795-801. PubMed ID: 14989491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
    Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
    Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
    Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.